Literature DB >> 20699280

Regulation of colon cancer cell proliferation and migration by MD-2 activity.

Virginie Grondin1, Philippe Seksik, Sylvie Dumont, Ginette Thomas, Germain Trugnan, Jean François Fléjou, Joelle Masliah, Dominique Wendum, Maria Bachelet.   

Abstract

Evidence suggests that signalling through lipopolysaccharide (LPS) has a significant role in the development of gastrointestinal malignancies. We previously demonstrated the critical role of myeloid differentiation (MD)-2, the essential co-receptor of LPS, for induction of cyclooxygenase (Cox)-2 in intestinal epithelial cells. Cyclooxigenase-2 was suggested to play a key role in colorectal cancer through the effects of prostaglandin (PG) E(2) generated. We, therefore, addressed the role of MD-2 in several parameters related to malignancy, namely cell proliferation and migration, using colon cancer cells (HT-29). We found that overexpression of MD-2 confers a significantly greater proliferation and migration capacity to these cells. MD-2-dependent proliferation and migration appeared independent of Cox-2 activity but was reduced by endothelial growth factor receptor (EGFR) neutralizing antibodies as well as by pharmacological inhibition of EGFR tyrosine phosphorylation. We propose that MD-2 overexpression contributes to tumour aggressiveness via a Cox-2-independent excessive EGFR signalling. Moreover, MD-2 expression levels were higher in tissue from patients with colorectal cancer as compared with paired control colorectal mucosa. Our data attest to a role of MD-2 activity in colon cancer epithelial cell proliferation and migration, which may be important in the general correlation between innate immune response, chronic inflammation, and cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20699280     DOI: 10.1177/1753425910375583

Source DB:  PubMed          Journal:  Innate Immun        ISSN: 1753-4259            Impact factor:   2.680


  11 in total

1.  LPS receptor subunits have antagonistic roles in epithelial apoptosis and colonic carcinogenesis.

Authors:  W-T Kuo; T-C Lee; H-Y Yang; C-Y Chen; Y-C Au; Y-Z Lu; L-L Wu; S-C Wei; Y-H Ni; B-R Lin; Y Chen; Y-H Tsai; J T Kung; F Sheu; L-W Lin; L C-H Yu
Journal:  Cell Death Differ       Date:  2015-01-30       Impact factor: 15.828

2.  Signatures of positive selection in LY96 gene in vertebrates.

Authors:  Tonghai Dou; Maobin Fu; Yixia Wang; Yang Zhao; Zhengshi Wang; Zhengqian Bian; Yan Zhou
Journal:  J Biosci       Date:  2013-12       Impact factor: 1.826

3.  Tuning the Dual Inhibition of Carbonic Anhydrase and Cyclooxygenase by Dihydrothiazole Benzensulfonamides.

Authors:  Rita Meleddu; Simona Distinto; Filippo Cottiglia; Rossella Angius; Marco Gaspari; Domenico Taverna; Claudia Melis; Andrea Angeli; Giulia Bianco; Serenella Deplano; Benedetta Fois; Sonia Del Prete; Clemente Capasso; Stefano Alcaro; Francesco Ortuso; Matilde Yanez; Claudiu T Supuran; Elias Maccioni
Journal:  ACS Med Chem Lett       Date:  2018-09-17       Impact factor: 4.345

Review 4.  Pathophysiological mechanisms of death resistance in colorectal carcinoma.

Authors:  Ching-Ying Huang; Linda Chia-Hui Yu
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

5.  Targeted extracellular nanoparticles enable intracellular detection of activated epidermal growth factor receptor in living brain cancer cells.

Authors:  Veronica Dudu; Veronica Rotari; Maribel Vazquez
Journal:  Nanomedicine       Date:  2011-05-20       Impact factor: 5.307

6.  Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway.

Authors:  Jian-Ming Huang; Guo-Nan Zhang; Yu Shi; Xiao Zha; Yi Zhu; Miao-Miao Wang; Qing Lin; Wen Wang; Hai-Yan Lu; Shi-Qi Ma; Jia Cheng; Bi-Fang Deng
Journal:  Sci Rep       Date:  2014-01-23       Impact factor: 4.379

7.  sTLR4/MD-2 complex inhibits colorectal cancer in vitro and in vivo by targeting LPS.

Authors:  Yan Zou; Fengxian Qin; Jifei Chen; Jie Meng; Liuhua Wei; Chunlin Wu; Qiaoyun Zhang; Dong Wei; Xiang Chen; Hao Wu; Xiaoli Chen; Shengming Dai
Journal:  Oncotarget       Date:  2016-08-09

Review 8.  Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers.

Authors:  Chun Wai Mai; Yew Beng Kang; Mallikarjuna Rao Pichika
Journal:  Onco Targets Ther       Date:  2013-11-05       Impact factor: 4.147

9.  Cathelicidin-mediated lipopolysaccharide signaling via intracellular TLR4 in colonic epithelial cells evokes CXCL8 production.

Authors:  Ravi Holani; Anshu Babbar; Graham A D Blyth; Fernando Lopes; Humberto Jijon; Derek M McKay; Morley D Hollenberg; Eduardo R Cobo
Journal:  Gut Microbes       Date:  2020-07-13

10.  Suppression of MD2 inhibits breast cancer in vitro and in vivo.

Authors:  S Zheng; W Fu; R Ma; Q Huang; J Gu; J Zhou; K Lu; G Guo
Journal:  Clin Transl Oncol       Date:  2021-03-17       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.